HOME >> BIOLOGY >> NEWS
Ronald Cape to receive 2007 Biotechnology Heritage Award

PHILADELPHIA and WASHINGTON, D.C.8 May 2007Chemical Heritage Foundation (CHF) and the Biotechnology Industry Organization (BIO) will present the ninth annual Biotechnology Heritage Award to Ronald Cape, cofounder of Cetus Corporation. Cape is a true visionary, a pioneer, and an entrepreneur gifted with considerable research and business skills. The award, sponsored by Invitrogen Corporation, will be presented at the 2007 BIO International Convention in Boston.

"Cetus Corporation is widely recognized as the first biotechnology company," said James C. Greenwood, president of BIO. "Ron Cape saw the potential of biotechnology even before recombinant DNA. He helped to create a new kind of company and with it launched the creation of a whole new industry."

About Ronald E. Cape

Cape, a partner at PureTech Ventures in Boston , cofounded Cetus in 1971 and served as its chairman for 20 years and CEO for 13 years, until Cetus merged with Chiron Corporation in 1991. Cetus was a pioneer in genetic engineering, developing a technology that was ultimately awarded a Nobel Prize. Cape was the founding chairman of Darwin Molecular Corporation, which was later sold to Chiroscience plc. He serves on the board of EntreMed, Inc. and Neurobiological Technologies, Inc. He also serves as a director for several privately held companies. Cape was a founding member of the Industrial Biotechnology Association (now BIO), where he served as president from 1983 to 1985. He is a fellow of the American Academy of Arts and Sciences, the American Academy of Microbiology, and the American Association for the Advancement of Science.

About the Biotechnology Heritage Award

The Biotechnology Heritage Award is presented yearly at a special ceremony during the BIO Annual International Convention to honor individuals who have contributed significantly to the growth of biotechnology through discovery, innovation, commercialization, and/or public und
'"/>

Contact: Neil Gussman
neilg@chemheritage.org
215-873-8262
Chemical Heritage Foundation
8-May-2007


Page: 1 2

Related biology news :

1. Joslins C. Ronald Kahn, MD, to discuss genetics of obesity at AACE meeting
2. Frances highest scientific honor awarded this year to Salk Institute scientist Ronald M. Evans
3. Carnegie Mellons Peter Adams receives EPA research grant
4. 2007 EURYI: 20 young researchers to receive Nobel Prize-sized awards for breakthrough ideas
5. Fedoroff, of Penn State, to receive National Medal of Science
6. Philadelphia ecologist receives top Mongolia honor
7. Nearly 90 percent of babies receive recommended newborn screening tests
8. VIB scientist receives major research grant
9. Maynard Olson receives $500,000 Gruber Genetics Prize
10. University of Cincinnati receives $1.7M to research molecular treatment of brain injury
11. UGA scientists receive $20M in federal bioenergy initiative

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology:
Cached News: